ArticleThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry2026
Relationship Between SSRI Exposure During Later Life and Clinical and Neuropathological Correlates of Dementia.
Article in The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesWhile depression is a risk factor for dementia, few studies examining the association between selective serotonin reuptake inhibitors (SSRIs) and dementia risk have controlled for confounding major depression and none to our knowledge have examined neuropathological outcomes. We examined the association between continuation of SSRIs in older adults with a lifetime history of depression and progression of cognitive and functional impairment, depression, and neuropathologic correlates of dementia.
designThis retrospective cohort study analyzed data from the National Alzheimer's Coordinating Center.
participantsParticipants aged 55 years or older were required to have clinician documented lifetime history of depression (n = 688). 463 (67.3%) reported continued SSRI use at every study visit prior to death. MEASUREMENTS: Primary clinical outcomes included the Clinical Dementia Rating-Sum of Boxes (CDR-SB), Functional Activities Questionnaire (FAQ), and the 15-item Geriatric Depression Scale (GDS-15). Neuropathological outcomes included assessments of Alzheimer's Disease (AD) pathology and cerebrovascular changes relevant to Vascular dementia (VaD).
resultsContinued SSRI use during later life was associated with a significantly slower increase on the CDR-SB compared to discontinuation of SSRIs. Rates of change on the FAQ and GDS-15 did not differ significantly between groups. While rates of AD pathology did not differ significantly between groups, continued SSRI use was associated with significantly lower rates of lacunes/infarcts on autopsy after controlling for smoking years and hypertension.
conclusionsPersistent use of SSRIs prior to death was associated with decreased progression of cognitive impairment and a nearly 50% reduction of lacunes/infarcts on autopsy. Our study is the first of our knowledge to identify associations between SSRI exposure in later life and neuropathological changes relevant to VaD on autopsy, which is considered the gold standard of diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.